"Resverlogix is a leading epigenetics company, creating first-in-class small molecule therapeutics for BET inhibition. Our exceptional staff and internationally respected experts are working diligently to safely bring to the market new therapeutics for our future patients. We continue our dedication to delivering concrete performance for our shareholders and diverse stakeholders."
Resverlogix Corp. (TSX: RVX) is developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. Apabetalone is the only selective BET bromodomain inhibitor in clinical trials. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. Apabetalone is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, Orphan diseases (PNH), and neurodegenerative diseases, while maintaining a well described safety profile. Resverlogix has commenced a Phase 3 clinical trial in CVD patients with type 2 DM and low HDL, with a primary endpoint of time to first occurrence of Major Adverse Cardiac Events (MACE).
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.